What You Should Know:
- Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures, including X-rays, CT scans, and MRIs.
- The development makes Abbott's systems the first and only patient-applied CGM sensors approved for use during these screenings, offering greater convenience and potential cost savings for people with diabetes.
Improving Diabetes
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Glooko Secures $100M, Appoints Mike Alvarez as New CEO
- Glooko, a global digital health company, has announced a successful Series F funding round, raising $100M to fuel its continued growth and product development led by Georgian, with participation from Health Catalyst Capital, Canaan, and other investors.
- In addition to this significant investment, Glooko also announced the appointment of Mike Alvarez as its new Chief Executive Officer.
Funding to Drive Product Innovation and Global Expansion
This substantial investment will support
Read More
Study: Twin Health Treats Hypertension in Patients with Type 2 Diabetes
What You Should Know:
- Twin Health, a company known for its Digital Twin™ AI platform that helps individuals achieve remission of type 2 diabetes, has announced promising results in a new study focused on hypertension.
- Published in the Journal of the American College of Cardiology, the study demonstrates that the platform can effectively help users control blood pressure and reduce their reliance on medication.
Addressing the Link Between Diabetes and Hypertension
High
Read More
Ascensia Launches World’s First One-Year CGM System, Eversense® 365
What You Should Know:
- Ascensia Diabetes Care has announced the U.S. launch of the Eversense® 365 continuous glucose monitoring (CGM) system, an advancement in diabetes management.
- Developed by Senseonics Holdings, Inc., Eversense 365 is the world's first and only CGM system to offer an entire year of continuous glucose monitoring with a single sensor. This innovative technology received FDA clearance last month for individuals with type 1 and type 2 diabetes aged 18 years
Read More
Dexcom and Beyond Type 2 Launch National Glucose Awareness Week with Retta
What You Should Know:
- DexCom, Inc., the global leader in real-time continuous glucose monitoring, and Beyond Type 2, a non-profit organization, are joining forces with actress Retta to launch the first-ever National Glucose Awareness Week.
- Taking place from September 23-29, 2024, this initiative aims to bridge the knowledge gap surrounding glucose health and empower individuals to take control of their well-being.
Addressing the Glucose Knowledge Gap
While glucose
Read More
ECHO Model Proven Effective for Improving Diabetes Care in Rural Areas
- A recent study has shed light on the significant potential of the ECHO Model in improving diabetes care in rural communities.
- The research, published in The Journal of General Internal Medicine, showed that rural healthcare providers participating in weekly ECHO telementoring sessions achieved comparable results to endocrinology specialists in academic medical centers when managing patients with diabetes.
Significant Reduction in A1c Levels
The study, which spanned five years
Read More
CGMs Through Medical Benefits: Improved Adherence and Cost Savings for Diabetes Patients, New Research Shows
What You Should Know:
- A research study by CCS, a leading chronic care management company, reveals that patients receiving continuous glucose monitoring (CGM) devices through medical benefits experience superior adherence and lower costs compared to those accessing them through pharmacy benefits.
- The JMIR Diabetes research — Exploring Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients with Diabetes: Impact of Device Sourcing, highlights
Read More
FDA Clears Eversense® 365: The World’s First One-Year CGM System
What You Should Know:
- Senseonics Holdings, Inc. and Ascensia Diabetes Care announced that the FDA has cleared the Eversense® 365 CGM system.
- This marks a significant advancement in diabetes management, offering a fully-implantable, long-term continuous glucose monitoring (CGM) solution for individuals with Type 1 and Type 2 diabetes aged 18 and older.
Eversense 365: Uninterrupted Living with Diabetes
Eversense 365 is set to transform the lives of people with diabetes by
Read More
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
DexCom Launches Non-Prescription Glucose Biosensor in U.S.
What You Should Know:
- Millions of Americans with Type 2 diabetes and prediabetes now have a new option for managing their glucose levels.
- DexCom, a leader in continuous glucose monitoring (CGM) technology announced the launch of Stelo, the first over-the-counter (OTC) glucose biosensor available in the US.
What is Stelo?
Stelo is a small, wearable sensor that provides real-time glucose readings directly to a smartphone app. Unlike traditional blood glucose meters,
Read More
